NASDAQ:OCUP Ocuphire Pharma (OCUP) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Ocuphire Pharma Stock (NASDAQ:OCUP) 30 days 90 days 365 days Advanced Chart Ad Timothy SykesTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…Click here to see a unique election-year trade Get Ocuphire Pharma alerts:Sign Up Key Stats Today's Range N/A50-Day Range$1.17▼$1.4652-Week Range N/AVolume676,700 shsAverage Volume171,840 shsMarket Capitalization$30.33 millionP/E RatioN/ADividend YieldN/APrice Target$16.00Consensus RatingBuy Company OverviewOcuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was founded in 2018 and is headquartered in Farmington Hills, Michigan.Read More… Tim Sykes’ Urgent Trade Alert: “Make this move now” (Ad)WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…Click here to see a unique election-year trade Ocuphire Pharma Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks46th Percentile Overall ScoreOCUP MarketRank™: Ocuphire Pharma scored higher than 46% of companies evaluated by MarketBeat, and ranked 583rd out of 997 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingOcuphire Pharma has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageOcuphire Pharma has only been the subject of 2 research reports in the past 90 days.Read more about Ocuphire Pharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Ocuphire Pharma are expected to decrease in the coming year, from ($1.11) to ($1.26) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ocuphire Pharma is -2.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ocuphire Pharma is -2.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Ocuphire Pharma's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.59% of the outstanding shares of Ocuphire Pharma have been sold short.Short Interest Ratio / Days to CoverOcuphire Pharma has a short interest ratio ("days to cover") of 6.4.Change versus previous monthShort interest in Ocuphire Pharma has recently decreased by 15.40%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOcuphire Pharma does not currently pay a dividend.Dividend GrowthOcuphire Pharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.59% of the outstanding shares of Ocuphire Pharma have been sold short.Short Interest Ratio / Days to CoverOcuphire Pharma has a short interest ratio ("days to cover") of 6.4.Change versus previous monthShort interest in Ocuphire Pharma has recently decreased by 15.40%, indicating that investor sentiment is improving significantly. News and Social Media2.2 / 5News Sentiment0.03 News SentimentOcuphire Pharma has a news sentiment score of 0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Ocuphire Pharma this week, compared to 1 article on an average week.Search Interest9 people have searched for OCUP on MarketBeat in the last 30 days. This is an increase of 80% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Ocuphire Pharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.70% of the stock of Ocuphire Pharma is held by insiders.Percentage Held by InstitutionsOnly 14.97% of the stock of Ocuphire Pharma is held by institutions.Read more about Ocuphire Pharma's insider trading history. Receive OCUP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ocuphire Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address OCUP Stock News HeadlinesFoundation Fighting Blindness: The RD Fund Announces Ocuphire Pharma's Acquisition of Opus GeneticsOctober 26 at 7:21 AM | finanznachrichten.deOcuphire Pharma, Inc. Announces Acquisition of Opus GeneticsOctober 26 at 7:21 AM | finanznachrichten.deWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.October 29, 2024 | Porter & Company (Ad)The RD Fund Announces Ocuphire Pharma's Acquisition of Opus GeneticsOctober 25, 2024 | prnewswire.comOcuphire Pharma Merges with Opus Genetics, Renamed Opus GeneticsOctober 24, 2024 | finance.yahoo.comOcuphire and Opus Genetics merge to develop IRD gene therapyOctober 24, 2024 | finance.yahoo.comOcuphire Pharma price target lowered to $10 from $18 at CanaccordOctober 24, 2024 | markets.businessinsider.comOcuphire Pharma Announces Acquisition of Opus GeneticsOctober 22, 2024 | globenewswire.comSee More Headlines OCUP Stock Analysis - Frequently Asked Questions How were Ocuphire Pharma's earnings last quarter? Ocuphire Pharma, Inc. (NASDAQ:OCUP) issued its quarterly earnings results on Tuesday, August, 13th. The company reported ($0.30) earnings per share for the quarter, missing analysts' consensus estimates of ($0.29) by $0.01. The business had revenue of $1.11 million for the quarter, compared to analyst estimates of $1.80 million. Ocuphire Pharma had a negative trailing twelve-month return on equity of 30.19% and a negative net margin of 85.75%. How do I buy shares of Ocuphire Pharma? Shares of OCUP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Ocuphire Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ocuphire Pharma investors own include NVIDIA (NVDA), Meta Platforms (META), Arista Networks (ANET), Broadcom (AVGO), ServiceNow (NOW), Novo Nordisk A/S (NVO) and e.l.f. Beauty (ELF). Company Calendar Last Earnings8/13/2024Today10/28/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:OCUP CUSIPN/A CIK1228627 Webwww.ocuphire.com Phone(248) 681-9815Fax240-268-5310Employees14Year FoundedN/APrice Target and Rating Average Stock Price Target$16.00 High Stock Price Target$20.00 Low Stock Price Target$10.00 Consensus RatingBuy Rating Score (0-4)3.25 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.49) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-9,990,000.00 Net Margins-85.75% Pretax Margin-85.68% Return on Equity-30.19% Return on Assets-27.55% Debt Debt-to-Equity RatioN/A Current Ratio10.68 Quick Ratio10.68 Sales & Book Value Annual Sales$16.45 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$2.20 per share Price / BookN/AMiscellaneous Outstanding Shares25,924,000Free Float24,469,000Market Cap$30.33 million OptionableOptionable Beta0.20 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report This page (NASDAQ:OCUP) was last updated on 10/29/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredElon Musk Drops Stunning Bombshell?Elon Musk just dropped a BOMBSHELL that could send shockwaves throughout the tech industry… While deliverin...Paradigm Press | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ocuphire Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ocuphire Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.